| NCT#: & Link | NCT05578092 |
| NCT QR Code |  |
| Available as of: | October 14, 2024 |
| Contract: | Optimal |
| Indication Category: | Solid Tumors, NSCLC |
| Study Sponsor: | Mirati Therapeutics |
| Protocol #: | 0902-001 |
| Title: | A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway |
| Highlight Details: | NSCLC previously treated with KRAS G12C inhibitor Solid Tumor not previously treated with KRAS G12C inhibitor This is a Phase 1/2, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy harboring mutations in the KRAS-MAPK pathways. |
| Biomarkers: | KRAS G12C |
| Indication: | NSCLC, Other Solid Tumors |
| Phase: | 1/2 |
| Treatment Line: | |
| Study Drug/Test Compound: | MRTX0902 + Adagrasib |
| Notes | |
| Recruitment Status: | Just In Time |
| Participating Institution: | Salinas Valley Health |
| Salinas Valley Health Clinical Research Program: | Terri Nielsen, MSJ, RN, CCRP, Clinical Research Program Manager, [email protected] |
A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway
